Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $71.40.
A number of equities research analysts recently weighed in on ARCT shares. Leerink Partnrs raised shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partners started coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They set an “outperform” rating and a $70.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th.
Get Our Latest Stock Report on Arcturus Therapeutics
Arcturus Therapeutics Trading Up 4.1 %
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The company had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. During the same period in the previous year, the firm posted ($1.98) earnings per share. As a group, equities research analysts forecast that Arcturus Therapeutics will post -2.6 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of ARCT. Millennium Management LLC grew its holdings in Arcturus Therapeutics by 250.1% during the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after purchasing an additional 396,505 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Arcturus Therapeutics by 22.4% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock valued at $38,061,000 after buying an additional 286,546 shares during the period. ARK Investment Management LLC boosted its holdings in shares of Arcturus Therapeutics by 16.3% in the second quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after buying an additional 275,315 shares during the period. Nordea Investment Management AB acquired a new position in shares of Arcturus Therapeutics in the first quarter valued at approximately $1,846,000. Finally, Granahan Investment Management LLC boosted its holdings in shares of Arcturus Therapeutics by 12.9% in the fourth quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock valued at $14,200,000 after buying an additional 51,504 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Featured Stories
- Five stocks we like better than Arcturus Therapeutics
- The 3 Best Fintech Stocks to Buy Now
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What Are Some of the Best Large-Cap Stocks to Buy?
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Using the MarketBeat Stock Split Calculator
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.